# Milestone M6: Reinforcement Learning for Treatment Optimization

**Deadline:** November 24, 23:59  
**Status:** üìã Planned

---

## üìã Objectives

1. **RL Environment Design**
   - Model cardiovascular treatment as an RL problem
   - Define state space (patient condition), action space (treatments), rewards (outcomes)
   - Create environment that simulates patient response to treatments
   - Incorporate insights from previous milestones (BN, HMM)

2. **RL Algorithm Implementation**
   - Implement Q-Learning for discrete action spaces
   - Apply Policy Gradient methods for more complex action spaces
   - Train agents to learn optimal treatment policies
   - Handle exploration vs exploitation trade-offs

3. **Policy Evaluation**
   - Evaluate learned treatment policies on validation patients
   - Compare RL-learned policies with observed clinical decisions
   - Analyze policy performance across different patient subgroups
   - Assess safety and efficacy of recommended treatments

4. **Integration and Validation**
   - Integrate probabilistic models (BN, HMM) with RL decision-making
   - Use HMM state predictions to inform RL state representation
   - Validate treatment recommendations against medical guidelines
   - Discuss clinical feasibility and ethical considerations

---

## üìä Specific Tasks

### 11.1. Environment Design
- [ ] Define RL state space using patient features (risk_score, symptoms, history)
- [ ] Design action space representing available treatments
- [ ] Create reward function based on utility and treatment outcomes
- [ ] Implement environment simulator using historical patient data
- [ ] Incorporate transition dynamics from HMM insights

### 11.2. State and Action Space Definition
- [ ] State: Patient condition (continuous/discrete features from dataset)
- [ ] Actions: Treatment options (medications, procedures, lifestyle changes)
- [ ] Rewards: Based on utility improvement, side effects, costs
- [ ] Terminal states: Treatment completion, adverse events
- [ ] State transitions: Informed by M5 HMM disease progression model

### 11.3. Q-Learning Implementation
- [ ] Implement tabular Q-Learning for discrete state/action spaces
- [ ] Design exploration strategy (Œµ-greedy, decay schedule)
- [ ] Train on historical patient treatment episodes
- [ ] Monitor convergence of Q-values
- [ ] Extract optimal policy from learned Q-function

### 11.4. Policy Gradient Methods
- [ ] Implement REINFORCE or Actor-Critic for continuous state spaces
- [ ] Design neural network policy architecture
- [ ] Train with policy gradient optimization
- [ ] Compare performance with Q-Learning approach
- [ ] Analyze learned policy characteristics

### 11.5. Policy Evaluation and Validation
- [ ] Evaluate policies on held-out patient trajectories
- [ ] Compare RL recommendations with actual clinical decisions
- [ ] Analyze treatment recommendations across patient subgroups
- [ ] Assess policy safety (avoid harmful treatment combinations)
- [ ] Validate against medical treatment guidelines

---

## üéØ Key Requirements

- **Environment**: Realistic simulation of patient-treatment interactions
- **Multiple Algorithms**: Both value-based (Q-Learning) and policy-based (REINFORCE/Actor-Critic)
- **Integration**: Use insights from BN (M2-M4) and HMM (M5) in RL design
- **Medical Validation**: Treatment policies should align with medical best practices
- **Safety**: Consider adverse effects and contraindications in reward design

---

## üìÅ Deliverables

1. **Jupyter Notebook**: `M6_G14.ipynb` with complete RL implementation
2. **Environment Design**: Clear specification of states, actions, rewards, transitions
3. **Algorithm Implementation**: Q-Learning and Policy Gradient with training curves
4. **Policy Analysis**: Learned treatment strategies with clinical interpretation
5. **Validation Results**: Comparison with clinical decisions and safety assessment

---

## üîó Connections to Other Milestones

- **M2-M4**: Uses BN insights about treatment-outcome relationships in reward design
- **M5**: Incorporates HMM disease progression dynamics in state transitions
- **M1**: Leverages data preprocessing for patient feature representation
- **Integration**: Combines all probabilistic modeling insights into decision-making framework

---

## üõ† Technical Notes

- **Library**: Use stable-baselines3, gym, or custom implementation for RL algorithms
- **Environment**: Can use OpenAI Gym interface for standardized RL environment
- **State Representation**: Balance between informative features and computational tractability
- **Reward Engineering**: Critical for learning clinically appropriate policies
- **Safety Constraints**: Consider hard constraints or penalty terms for dangerous actions
- **Evaluation**: Use both RL metrics (cumulative reward) and clinical metrics (patient outcomes)
- **Ethical Considerations**: Discuss limitations and requirements for clinical deployment

---

## üéØ Success Criteria

M6 is considered complete when:

- [ ] RL environment accurately represents treatment decision problem
- [ ] Q-Learning and Policy Gradient algorithms successfully train
- [ ] Learned policies show improvement over random treatment selection
- [ ] Treatment recommendations are clinically plausible and safe
- [ ] Integration with previous milestones is demonstrated
- [ ] Clinical validation and ethical considerations are addressed

---

## üöÄ Final Integration

This milestone completes the probabilistic ML pipeline:
1. **M0-M1**: Data understanding and preprocessing
2. **M2-M4**: Bayesian Networks for relationship modeling
3. **M5**: HMM for temporal disease progression
4. **M6**: RL for optimal treatment decision-making

The final system combines exploratory analysis, probabilistic reasoning, temporal modeling, and decision optimization for comprehensive cardiovascular disease management.